CRIS

Curis, Inc. [CRIS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CRIS Stock Summary

Top CRIS Correlated Resources

CRIS


Top 10 Correlated ETFs

CRIS


Top 10 Correlated Stocks

CRIS


In the News

09:04 10 Dec 2023 CRIS

Curis's stock rises as analysts see ‘the next Pharmacyclics'

Shares of Curis Inc. CRIS, +4.23% gained nearly 6% premarket on Friday after Truist Securities analysts initiated coverage of the cancer-focused biotech company with a buy rating.

02:32 10 Dec 2023 CRIS

Curis, Inc. (CRIS) Q3 2023 Earnings Call Transcript

Curis, Inc. (NASDAQ:CRIS ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Conference Call Participants Yale Jen - Laidlaw & Co. Operator Good morning, and welcome to Curis' Third Quarter 2023 Business Update Call. All participants will be in a listen-only mode.

08:13 10 Dec 2023 CRIS

Curis to Present at Upcoming Healthcare Conferences in September

LEXINGTON, Mass. , Sept. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The H.C.

07:32 10 Dec 2023 CRIS

Curis (CRIS) Reports Q2 Loss, Misses Revenue Estimates

Curis (CRIS) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.

06:25 10 Dec 2023 CRIS

Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023

LEXINGTON, Mass. , July 27, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that the Company will release its second quarter 2023 financial results on Thursday, August 3, 2023, after the close of U.S. markets.

07:01 10 Dec 2023 CRIS

Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates

Curis (CRIS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.18 per share a year ago.

08:00 10 Dec 2023 CRIS

Curis to Present at Upcoming Healthcare Conferences in April

LEXINGTON, Mass. , April 3, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The Cantor Fitzgerald Future of Oncology Symposium, being held virtually from April 3 – 5, 2023.

12:22 10 Dec 2023 CRIS

Curis, Inc. (CRIS) Q4 2022 Earnings Call Transcript

Curis, Inc. (NASDAQ:CRIS ) Q4 2022 Earnings Conference Call March 13, 2023 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer James Dentzer - President and Chief Executive Officer Robert Martell - Head of R&D Conference Call Participants Ed White - H.C. Wainwright Soumit Roy - JonesTrading Yale Jen - Laidlaw & Company Operator Good morning, and welcome to the Curis Fourth Quarter 2022 Business Update Call.

10:44 10 Dec 2023 CRIS

Curis (CRIS) Reports Q4 Loss, Misses Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of 14.29% and 4.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

07:09 10 Dec 2023 CRIS

Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call

LEXINGTON, Mass. , March 8, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it is rescheduling its fourth quarter business update and quarterly investor conference call previously scheduled for Thursday, March 9, 2023 at 4:30 p.m.

CRIS Financial details

Company Rating
Buy
Market Cap
67.86M
Income
-48.07M
Revenue
10.21M
Book val./share
5.17
Cash/share
11.97
Dividend
-
Dividend %
-
Employees
51
Optionable
No
Shortable
Yes
Earnings
02 Nov 2023
P/E
-1.37
Forward P/E
-1.49
PEG
1.01
P/S
6.64
P/B
2.23
P/C
0.96
P/FCF
-2.21
Quick Ratio
5.73
Current Ratio
6.19
Debt / Equity
0.15
LT Debt / Equity
0.1
-
-
EPS (TTM)
-9.56
EPS next Y
-7.72
EPS next Q
-2.34
EPS this Y
16.82%
EPS next Y
-19.22%
EPS next 5Y
-24.06%
EPS last 5Y
-8.06%
Revenue last 5Y
-0.52%
Revenue Q/Q
28.95%
EPS Q/Q
-13.77%
-
-
-
-
SMA20
127.44%
SMA50
980.36%
SMA100
1357.83%
Inst Own
30.85%
Inst Trans
1.04%
ROA
-53%
ROE
-138%
ROC
-0.6%
Gross Margin
98%
Oper. Margin
-454%
Profit Margin
-471%
Payout
-
Shs Outstand
5.88M
Shs Float
4.86M
-
-
-
-
Target Price
-
52W Range
0.38-15.11
52W High
-
52W Low
-
RSI
60.52
Rel Volume
0.51
Avg Volume
158.02K
Volume
81K
Perf Week
-6.56%
Perf Month
184.94%
Perf Quarter
1290.36%
Perf Half Y
1290.36%
-
-
-
-
Beta
3.931
-
-
Volatility
1.27%, 3.14%
Prev Close
-12.77%
Price
11.54
Change
-9.7%

CRIS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
6.36.034.452.332.18
Net income per share
-19.67-22.18-14.33-11.06-12.92
Operating cash flow per share
-18.16-15.8-10.58-8.22-11.64
Free cash flow per share
-18.21-15.82-10.86-8.22-11.73
Cash per share
14.6612.3869.2425.3118.34
Book value per share
-2.72-20.4453.719.819.97
Tangible book value per share
-8.14-25.855017.858.05
Share holders equity per share
-2.72-20.4453.719.819.97
Interest debt per share
27.963.025.243.032.47
Market cap
1.14M2.82M19.93M21.79M2.57M
Enterprise value
12.99M-12.44M-102.02M-13.18M-10.35M
P/E ratio
-0.04-0.08-0.57-0.43-0.04
Price to sales ratio
0.110.281.842.050.25
POCF ratio
-0.04-0.11-0.77-0.58-0.05
PFCF ratio
-0.04-0.11-0.75-0.58-0.05
P/B Ratio
-0.25-0.080.150.240.06
PTB ratio
-0.25-0.080.150.240.06
EV to sales
1.25-1.24-9.42-1.24-1.02
Enterprise value over EBITDA
-0.450.524.110.320.2
EV to operating cash flow
-0.430.473.960.350.19
EV to free cash flow
-0.430.473.860.350.19
Earnings yield
-28.51-13.05-1.75-2.32-23.49
Free cash flow yield
-26.39-9.31-1.33-1.73-21.32
Debt to equity
-9.4200.060.10.14
Debt to assets
1.1300.040.060.06
Net debt to EBITDA
-0.410.644.910.850.24
Current ratio
4.253.7812.848.086.96
Interest coverage
-7.47-5.03-4.89-9.41-11.11
Income quality
0.920.820.860.830.96
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.421.161.121.621.93
Research and developement to revenue
2.342.232.133.284.26
Intangibles to total assets
0.240.260.040.060.08
Capex to operating cash flow
000.0300.01
Capex to revenue
-0.010-0.060-0.04
Capex to depreciation
-0.48-0.33-4.70-1.79
Stock based compensation to revenue
0.380.270.250.50.66
Graham number
34.67101.01131.5970.2253.83
ROIC
-0.790.83-0.2-0.45-0.99
Return on tangible assets
-1.15-1.41-0.18-0.33-0.6
Graham Net
-9.58-27.7839.819.925.16
Working capital
20.76M18.22M172.36M126M76.42M
Tangible asset value
-13.48M-42.89M121.69M81.73M37.57M
Net current asset value
-14.73M-44.26M113.23M72.2M26.94M
Invested capital
-9.4200.060.10.14
Average receivables
2.97M3.05M3.14M3.13M3.1M
Average payables
4.17M3.69M4.32M5.29M4.81M
Average inventory
-413.5K-460.5K-246.5K-1.47M-2.71M
Days sales outstanding
100.25118.36102.51110.5106.86
Days payables outstanding
1.89K3.24K2.85K4.39K4.53K
Days of inventory on hand
-536.15-68.21-272.72-1.74K-4.1K
Receivables turnover
3.643.083.563.33.42
Payables turnover
0.190.110.130.080.08
Inventory turnover
-0.68-5.35-1.34-0.21-0.09
ROE
7.251.09-0.27-0.56-1.3
Capex per share
-0.05-0.02-0.280-0.09

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.60.60.480.450.5
Net income per share
-2.98-2.58-2.38-2.47-2.13
Operating cash flow per share
-2.8-2.54-2.53-1.630.29
Free cash flow per share
-2.81-2.54-2.53-1.630.29
Cash per share
21.0417.7614.8513.1311.97
Book value per share
11.899.667.575.425.17
Tangible book value per share
9.977.795.723.573.6
Share holders equity per share
11.899.667.575.425.17
Interest debt per share
1.111.741.260.830.76
Market cap
3.28M2.65M2.9M4.01M37.7M
Enterprise value
-22.37M-10.27M-25.12M-12.43M16.32M
P/E ratio
-0.06-0.05-0.06-0.08-0.77
Price to sales ratio
1.160.921.261.8313.31
POCF ratio
-0.25-0.22-0.24-0.5123.09
PFCF ratio
-0.25-0.22-0.24-0.5123.09
P/B Ratio
0.060.060.080.151.27
PTB ratio
0.060.060.080.151.27
EV to sales
-7.92-3.56-10.94-5.665.76
Enterprise value over EBITDA
1.8312.161.1-1.32
EV to operating cash flow
1.70.842.061.5810
EV to free cash flow
1.70.842.061.5810
Earnings yield
-4.26-4.69-3.96-2.98-0.32
Free cash flow yield
-4.01-4.63-4.21-1.960.04
Debt to equity
0.080.140.170.130.15
Debt to assets
0.030.060.070.040.05
Net debt to EBITDA
2.11.262.411.461.73
Current ratio
7.696.967.077.016.19
Interest coverage
-12.32-6.19170.99-19.030
Income quality
0.991.081.060.660
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.611.52.071.931.68
Research and developement to revenue
3.833.023.984.563.66
Intangibles to total assets
0.070.080.10.110.1
Capex to operating cash flow
00000
Capex to revenue
-0.020000
Capex to depreciation
-0.850000
Stock based compensation to revenue
0.470.60.610.650.58
Graham number
28.2423.6720.1317.3815.74
ROIC
-0.21-0.2-0.25-0.39-0.33
Return on tangible assets
-0.12-0.12-0.13-0.16-0.15
Graham Net
7.252.881.491.84
Working capital
91.98M76.42M64.15M58.17M64.65M
Tangible asset value
46.76M37.57M27.61M17.24M20.61M
Net current asset value
38.61M26.94M16.75M9.77M16.71M
Invested capital
0.080.140.170.130.15
Average receivables
2.64M2.93M2.64M2.35M2.62M
Average payables
5.63M4.47M2.92M2.66M3.95M
Average inventory
0-1.44M-3.09M-1.65M272K
Days sales outstanding
91.9492.7490.6797.7490.48
Days payables outstanding
8.36K4.05K9.91K3.27K7.83K
Days of inventory on hand
0-3.66K-12.38K0816
Receivables turnover
0.980.970.990.920.99
Payables turnover
0.010.020.010.030.01
Inventory turnover
0-0.02-0.0100.11
ROE
-0.25-0.27-0.31-0.46-0.41
Capex per share
-0.010000

CRIS Frequently Asked Questions

What is Curis, Inc. stock symbol ?

Curis, Inc. is a US stock , located in Lexington of Ma and trading under the symbol CRIS

What is Curis, Inc. stock quote today ?

Curis, Inc. stock price is $11.54 today.

Is Curis, Inc. stock public?

Yes, Curis, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Similar Market Cap